 EMERYVILLE, Calif., Dec. 21, 2020 GLOBE NEWSWIRE -- Zogenix NASDAQ: ZGNX, a global biopharmaceutical company developing rare disease therapies, announced today that the European Commission EC has granted marketing authorization for FINTEPLA fenfluramine oral solution for the treatment of seizures associated with Dravet syndrome as an add-on therapy to other anti-epileptic medicines for patients two years of age and older. Dravet syndrome is a rare, lifelong epilepsy that begins in infancy and is marked by severe refractory seizures, frequent medical emergencies, significant cognitive and behavioral impairments, and an increased risk of sudden premature death SUDEP. 